News Update

VIDEO: IBEX’S VISION FOR THE FUTURE OF CANCER DIAGNOSTICS
Watch our Co-Founder and CEO, Joseph Mossel, discuss the challenges pathologists are facing and how Ibex Medical Analytics makes cancer diagnosis more efficient and more accurate, using artificial intelligence (AI).

WATCH THE VIDEO

MEET US AT APC 2019
Ibex Medical Analytics will be attending the  APC 2019 Annual meeting in Boston.  Our leadership team will be on-site (booth #S14) to discuss Ibex’s vision for using artificial intelligence (AI) in cancer diagnostics and demonstrate our solution for detecting prostate cancer. Be sure to pay our booth a visit, we would love to see you there!
July 21-24, 2019. Seaport Hotel & Trade Show Center, Boston, MA

SCHEDULE A MEETING.

IBEX MEDICAL ANALYTICS JUST COMPLETED ITS ROUND A
We are happy to share that we recently completed an $11 Million Series A funding round. We intend to use these funds to grow our R&D team, accelerate product development and expand our footprint in pathology labs globally.

READ THE FULL ANNOUNCEMENT

THE ROLE OF CANCER GRADING – PROSTATE CANCER TEST CASE
Cancer grading can immensely benefit from artificial intelligence (AI). Convolutional neural networks (CNNs) are perfectly suitable for identifying subtle, complex patterns and classify them with high accuracy. The more complex grading can be beneficial in achieving finer and more accurate correlations with available therapies and with patient outcomes, thus improving patient care and reducing spend on ineffective treatments. In a recent article, we evaluate prostate cancer as a test case for demonstrating the tremendous potential of AI in cancer grading. READ MORE